The contemporary management of prostate cancer
Abstract
Abstract Prostate cancer is the most common cancer in two thirds of the world, with an expected doubling in both incidence and mortality in the next two decades. No strong environmental associations exist for the development of prostate cancer; therefore, lifestyle measures are unlikely to mitigate this increasing burden. The last three decades have seen rapid developments in the diagnostic and therapeutic landscape of prostate cancer, including multiparametric magnetic resonance imaging, positron emission tomography, robotic surgery, image‐guided hypofractionated and stereotactic radiotherapy, novel anti‐androgens and radioligand therapies. Prostate cancer is unique in that not everyone with a diagnosis needs treatment, and active surveillance is the preferred option for some. This review discusses the contemporary management of all stages of prostate cancer in the light of these modern developments, enabling holistic individualization of treatment, and describes the promise of future research to further improve outcomes.
Article Details
Authors (12)
Deep Chakrabarti
Uro‐Oncology Unit The Royal Marsden National Health Service Foundation Trust Sutton and London UK
Peter Albertsen
UConn Health Farmington Connecticut USA
Aidan Adkins
Europa Uomo Antwerp Belgium
Amar Kishan
Ronald Reagan UCLA Medical Center University of California‐Los Angeles Medical Center Santa Monica California USA
Vedang Murthy
Tata Memorial Hospital and Advanced Center for Treatment Research and Education in Cancer Homi Bhabha National Institute Mumbai India
Chris Parker
Uro‐Oncology Unit The Royal Marsden National Health Service Foundation Trust Sutton and London UK
Angela Pathmanathan
Uro‐Oncology Unit The Royal Marsden National Health Service Foundation Trust Sutton and London UK
Alison Reid
Uro‐Oncology Unit The Royal Marsden National Health Service Foundation Trust Sutton and London UK
Oliver Sartor
Mayo Clinic Comprehensive Cancer Center Mayo Clinic Rochester Minnesota USA
Nicholas Van As
Uro‐Oncology Unit The Royal Marsden National Health Service Foundation Trust Sutton and London UK
Jochen Walz
Institut Paoli‐Calmettes Cancer Center Marseille France
Alison Tree
Uro‐Oncology Unit The Royal Marsden National Health Service Foundation Trust Sutton and London UK